HCA Healthcare, Inc. (HCA)
Official siteHEALTHCARE • MEDICAL CARE FACILITIES • NYSE
Market Cap: $104.25B
Last updated: Nov 17, 2026 at 11:06 AM ET
HCA Healthcare, Inc. (HCA) Earnings: Report Dates and Results
HCA Healthcare (HCA) is expected to report earnings on Jan 25, 2027. In the quarter ended Sep 30, 2026, HCA Healthcare reported EPS of $7.22, above the $6.74 estimate. It beat the EPS estimate in each of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
HCA has an expected report date of Jan 25, 2027. Analysts' consensus for the quarter ending Dec 31, 2026 is 3.4% above the $8.01 reported for the quarter ended Dec 31, 2025.
HCA Earnings Call
The latest HCA earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptEarnings History
Of the 40 quarters below that had an estimate, HCA beat 28, missed 9 and matched 3. Revenue for the quarter ended Sep 30, 2026 was $19.85B, up 3.6% from $19.16B a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | $7.22 | $6.74 | $5.83 - $7.35 | +7.12% | Beat | +3.7% | 20 | 0 up, 3 down | Oct 27, 2026 | $19.85B |
| Jun 30, 2026 | $7.59 | $7.57 | $7.28 - $7.62 | +0.26% | Beat | +11.0% | 15 | 1 up, 1 down | Jul 24, 2026 | $20.23B |
| Mar 31, 2026 | $7.15 | $7.13 | $6.72 - $7.65 | +0.28% | Beat | +10.9% | 19 | 0 up, 2 down | Apr 24, 2026 | $19.11B |
| Dec 31, 2025 | $8.01 | $7.48 | $7.18 - $7.71 | +7.09% | Beat | +28.8% | 20 | 11 up, 7 down | Jan 27, 2026 | $19.51B |
| Sep 30, 2025 | $6.96 | $5.73 | $5.38 - $5.98 | +21.47% | Beat | +42.0% | 19 | 2 up, 3 down | Oct 24, 2025 | $19.16B |
| Jun 30, 2025 | $6.84 | $6.32 | $5.98 - $6.70 | +8.23% | Beat | +24.4% | 19 | 1 up, 2 down | Jul 25, 2025 | $18.61B |
| Mar 31, 2025 | $6.45 | $5.75 | $5.48 - $5.95 | +12.17% | Beat | +20.3% | 19 | 0 up, 1 down | Apr 25, 2025 | $18.32B |
| Dec 31, 2024 | $6.22 | $6.14 | $5.84 - $7.04 | +1.30% | Beat | +5.4% | 18 | 0 up, 1 down | Jan 24, 2025 | $18.29B |
| Sep 30, 2024 | $4.90 | $4.98 | $4.75 - $5.55 | -1.61% | Miss | +25.3% | 14 | 2 up, 0 down | Oct 25, 2024 | $17.49B |
| Jun 30, 2024 | $5.50 | $4.93 | $4.15 - $5.44 | +11.56% | Beat | +28.2% | 16 | 3 up, 0 down | Jul 23, 2024 | $17.49B |
| Mar 31, 2024 | $5.36 | $5.09 | $4.02 - $5.69 | +5.30% | Beat | +8.7% | 17 | 2 up, 0 down | Apr 26, 2024 | $17.34B |
| Dec 31, 2023 | $5.90 | $5.05 | $4.91 - $5.37 | +16.83% | Beat | +27.2% | 15 | 1 up, 0 down | Jan 30, 2024 | $17.30B |
| Sep 30, 2023 | $3.91 | $3.97 | $3.72 - $4.32 | -1.51% | Miss | -0.5% | 15 | 1 up, 1 down | Oct 24, 2023 | $16.21B |
| Jun 30, 2023 | $4.29 | $4.24 | $3.93 - $4.37 | +1.18% | Beat | +1.9% | 16 | 1 up, 0 down | Jul 27, 2023 | $15.86B |
| Mar 31, 2023 | $4.93 | $3.92 | $3.46 - $4.20 | +25.77% | Beat | +19.7% | 19 | 3 up, 2 down | Apr 21, 2023 | $15.59B |
| Dec 31, 2022 | $4.64 | $4.79 | $4.34 - $5.27 | -3.13% | Miss | +5.0% | 18 | 2 up, 0 down | Jan 27, 2023 | $15.50B |
| Sep 30, 2022 | $3.93 | $3.86 | $3.61 - $4.24 | +1.81% | Beat | -14.0% | 20 | 2 up, 0 down | Oct 21, 2022 | $14.97B |
| Jun 30, 2022 | $4.21 | $3.71 | $3.15 - $4.14 | +13.48% | Beat | -3.7% | 21 | 1 up, 1 down | Jul 22, 2022 | $14.82B |
| Mar 31, 2022 | $4.12 | $4.24 | $3.84 - $4.60 | -2.83% | Miss | -0.5% | 20 | 0 up, 1 down | Apr 22, 2022 | $14.95B |
| Dec 31, 2021 | $4.42 | $4.52 | $4.18 - $5.21 | -2.21% | Miss | +7.0% | 21 | 1 up, 0 down | Jan 27, 2022 | $15.06B |
| Sep 30, 2021 | $4.57 | $4.01 | $3.55 - $5.90 | +13.97% | Beat | +138.0% | 21 | N/A | Oct 22, 2021 | $15.28B |
| Jun 30, 2021 | $4.37 | $3.16 | $2.74 - $3.64 | +38.29% | Beat | +191.3% | 19 | N/A | Jul 20, 2021 | $14.44B |
| Mar 31, 2021 | $4.14 | $3.33 | $2.88 - $3.79 | +24.32% | Beat | +77.7% | 17 | N/A | Apr 22, 2021 | $13.98B |
| Dec 31, 2020 | $4.13 | $3.59 | $3.24 - $4.05 | +15.04% | Beat | +33.7% | 18 | N/A | Feb 2, 2021 | $14.29B |
| Sep 30, 2020 | $1.92 | $2.26 | $1.68 - $4.80 | -15.04% | Miss | -13.9% | 18 | N/A | Oct 26, 2020 | $13.31B |
| Jun 30, 2020 | $1.50 | -$0.33 | -$2.66 - $1.22 | +554.55% | Beat | -32.1% | 18 | N/A | Jul 22, 2020 | $11.07B |
| Mar 31, 2020 | $2.33 | $2.65 | $1.10 - $3.04 | -12.08% | Miss | -21.5% | 20 | N/A | Apr 21, 2020 | $12.86B |
| Dec 31, 2019 | $3.09 | $3.09 | $2.89 - $3.25 | 0.00% | In line | +3.3% | 23 | N/A | Jan 28, 2020 | $13.52B |
| Sep 30, 2019 | $2.23 | $2.13 | $1.92 - $2.31 | +4.69% | Beat | +3.2% | 23 | N/A | Oct 29, 2019 | $12.69B |
| Jun 30, 2019 | $2.21 | $2.46 | $2.25 - $2.70 | -10.16% | Miss | -3.5% | 22 | N/A | Jul 30, 2019 | $12.60B |
| Mar 31, 2019 | $2.97 | $2.33 | $2.16 - $2.55 | +27.47% | Beat | +27.5% | 22 | N/A | Apr 30, 2019 | $12.52B |
| Dec 31, 2018 | $2.99 | $2.58 | $2.46 - $2.71 | +15.89% | Beat | +40.4% | 24 | N/A | Jan 29, 2019 | $12.27B |
| Sep 30, 2018 | $2.16 | $1.91 | $1.61 - $2.09 | +13.09% | Beat | +78.5% | 20 | N/A | Oct 30, 2018 | $11.45B |
| Jun 30, 2018 | $2.29 | $2.16 | $2.04 - $2.35 | +6.02% | Beat | +30.9% | 20 | N/A | Jul 25, 2018 | $11.53B |
| Mar 31, 2018 | $2.33 | $2.07 | $1.93 - $2.40 | +12.56% | Beat | +33.9% | 21 | N/A | May 1, 2018 | $11.42B |
| Dec 31, 2017 | $2.13 | $1.88 | $1.77 - $2.04 | +13.30% | Beat | +12.7% | 21 | N/A | Jan 30, 2018 | $11.56B |
| Sep 30, 2017 | $1.21 | $1.21 | N/A | 0.00% | In line | -24.8% | 18 | N/A | Oct 31, 2017 | $10.70B |
| Jun 30, 2017 | $1.75 | $1.81 | $1.70 - $1.89 | -3.31% | Miss | +5.4% | 22 | N/A | Jul 25, 2017 | $10.73B |
| Mar 31, 2017 | $1.74 | $1.74 | N/A | 0.00% | In line | +1.8% | N/A | N/A | May 2, 2017 | $10.62B |
| Dec 31, 2016 | $1.89 | $1.78 | N/A | +6.18% | Beat | +11.8% | N/A | N/A | Jan 31, 2017 | $8.25B |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was $28.26, up 28.6% from the year before. It was $6.87 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | $28.26 | +28.6% |
| Dec 31, 2024 | $21.98 | +15.5% |
| Dec 31, 2023 | $19.03 | +12.6% |
| Dec 31, 2022 | $16.90 | -3.4% |
| Dec 31, 2021 | $17.50 | +77.1% |
| Dec 31, 2020 | $9.88 | -5.9% |
| Dec 31, 2019 | $10.50 | +7.5% |
| Dec 31, 2018 | $9.77 | +43.0% |
| Dec 31, 2017 | $6.83 | N/A |
| Dec 31, 2016 | $6.87 | N/A |
Earnings Calls
The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 8,500 words across 23 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q3 | Sep 30, 2026 | 8,457 | 23 | |
| 2026Q2 | Jun 30, 2026 | 7,058 | 20 | |
| 2026Q1 | Mar 31, 2026 | 8,323 | 20 | |
| 2025Q4 | Dec 31, 2025 | 8,768 | 20 | |
| 2025Q3 | Sep 30, 2025 | 4,072 | 10 | |
| 2025Q2 | Jun 30, 2025 | 7,574 | 20 | |
| 2025Q1 | Mar 31, 2025 | 8,451 | 21 | |
| 2024Q4 | Dec 31, 2024 | 8,219 | 22 |
2026Q3 Earnings Call
Opening remarks
Frank George Morgan Vice President of Investor Relations Good morning, and welcome to everyone on today's call. With me this morning is our CEO, Samuel N. Hazen, and our CFO, Michael A. Marks. Samuel and Mike will provide some prepared remarks, and then we will take your questions. Before I turn the call over to Samuel, let me remind everyone that should today's call contain any forward-looking statements, they are based on management's current expectations. Numerous risks, uncertainties, and other factors may cause actual results to differ materially from those that might be expressed today. More information on forward-looking statements and these factors is listed in today's press release and in our various SEC filings. On this morning's call, we may reference measures such as adjusted EBITDA, which is a non-GAAP financial measure. A table providing supplemental information on adjusted EBITDA and reconciling net income attributable to HCA Healthcare, Inc., is included in today's release. This morning's call is being recorded, and a replay of the call will be available later today. With that, I will now turn the call over to Samuel N. Hazen.
Samuel N. Hazen CEO Good morning, and thank you for joining the call. The company's results in the third quarter reflected improvement in key areas of our business. First, demand for our services continued to grow at a solid rate. Adjusted admissions on a same-facility basis grew 3%, compared to 2.3% year to date. Within this growth, insured volumes grew faster in the quarter than in the first half of the year. The third quarter reflected the 22nd consecutive quarter of volume growth for the company. Second, revenue per adjusted admission for our insured business, excluding supplemental payments, increased at a higher rate than in the first half of the year. This increase partially offset the payer-mix pressure from continued volume declines for patients who were formerly covered in health insurance exchanges and are now uninsured. Additionally, we had a modest incremental net benefit of $50 million in the quarter from Medicaid supplemental payment programs, primarily related to a recently approved Virginia program. These factors, coupled with improved cost results, contributed to solid financial performance in the quarter that slightly exceeded our expectations. Diluted earnings per share, as adjusted, increased almost 4%. I have often mentioned that HCA has strong staying power because of our scale, the important role we play in providing services to communities, and our disciplined culture. Despite the challenges this year brought about by federal policy changes, we have continued to move the company forward and believe we are positioned to end the year positively. As we look ahead to 2027, let me share a few preliminary observations around certain aspects of our business before we provide our full-year guidance in January.
Frequently Asked Questions About HCA
When is HCA Healthcare's next earnings date?
HCA Healthcare's next earnings report is expected for Jan 25, 2027.
Did HCA beat earnings estimates last quarter?
Yes. HCA Healthcare reported EPS of $7.22 for the quarter ended Sep 30, 2026, above the $6.74 estimate, a 7.12% surprise.
What EPS do analysts expect from HCA next quarter?
The consensus EPS estimate for HCA Healthcare for the quarter ending Dec 31, 2026 is $8.28 from 24 analysts, with estimates from $7.72 to $8.94.
How often does HCA beat earnings estimates?
HCA Healthcare beat the EPS estimate in each of the last 8 quarters, with an average surprise of +7.24%.
HCA pages: Overview, Dividends, Earnings, Forecast, Financials, Valuation, Competitors